Zytiga Sales Soar

Zytiga sales have exceeded all expectations and is one of the fastest selling cancer therapies ever launched.

Comparing Zytiga and Provenge Sales Trends
$ millions 1Q, 2011 2Q, 2011 3Q, 2011 4Q, 2011 FY, 2011

Worldwide
Provenge 28 50 64 82 224
Zytiga 0 55 100 141 296
Total 28 105 164 223 520

US
Provenge 28 50 64 82 224
Zytiga 0 36 62 85 182
Total 28 85 126 167 406

Foreign
Provenge 0 0 0 0 0
Zytiga 0 19 38 56 114
Total 0 19 38 56 114

Latest sales figures for Zytiga showed that it had outsold its nearest rival Provenge in the first quater immediately following its Launch. Here Zytiga sales worldwide were $ 55 M whilst Provenge was $ 50 M. Sales of Zytiga have been increasing by over $ 10 M month by month culminating in a final quaterly sales figure of $ 141 M. The final 2011 sales of Zytiga was $ 296 M and sales for 2012 are projected to reach $ 1 Billion with quaterly sales set to exceed $ 250 M.